OS Therapies ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming ...
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
EQT Foundation is announcing a new global call for proposals under its Breakthrough Science grants program, awarding between ?25,000 to ?100,000 for pioneering researchers tackling women's health ...
AM CT on Friday, March 28, 2025PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company ...
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PDTM 2025 <li /> A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback